MedTrace Logo

WRITE: Written Imaginal Thinking Exercise Study

NCT07464158 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of the study is to investigate and compare the effects of three different versions of a future imaginal writing exercise (worst-case scenario, neutral future scenario, best-case scenario) for individuals with elevated social anxiety symptoms. Participants (N=270) will be recruited through the online platform, Prolific, and will be randomly assigned to one of three writing exercise conditions. Participants will complete three study sessions across approximately three weeks. Study session 1 (T1) will consist of baseline assessments and pre-writing ratings, a future imaginal writing exercise, and then post-writing ratings. Study session 2 (T2) will occur approximately one week later and will consist of mid-study assessments and pre-writing ratings, a second, repeated future imaginal writing exercise, and then post-writing ratings. Finally, study session 3 (T3) will occur approximately one week later (approximately two weeks after T1) and will consist of follow-up assessments and repeated post-writing ratings.

Conditions

Interventions

BEHAVIORAL

Worst-Case Scenario Written Exposure Exercise

Written exposure exercise about an imagined future worst-case scenario.

BEHAVIORAL

Neutral Future Scenario Written Exercise

Written exercise about an imagined neutral future scenario.

BEHAVIORAL

Best-Case Scenario Written Exposure Exercise

Written exposure exercise about an imagined future best-case scenario.

Sponsors & Collaborators

  • University of Colorado, Boulder

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-21
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464158 on ClinicalTrials.gov